UCB to Acquire Candid for up to $2.2B, Expanding Presence in TCE Antibodies for Immunology
UCB said its planned acquisition of Candid plus an earlier licensing deal with Antengene reflect a platform-based strategy designed to strengthening its ability to address antibody mediated autoimmune diseases through multiple approaches rather than rely on a single asset or modality. The post UCB to Acquire Candid for up to $2.2B, Expanding Presence in TCE Antibodies for Immunology appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.